Us Worldmeds

Us Worldmeds company information, Employees & Contact Information

Explore related pages

Related company profiles:

US WorldMeds is a specialty pharmaceutical company that develops, licenses, and brings to market unique healthcare products designed to improve the lives of patients with challenging conditions and unmet medical needs. Organized on March 23, 2001 by current CEO Paul Breckinridge "Breck" Jones, US WorldMeds holds true to Breck’s vision of creating a sustainable, privately held specialty pharmaceutical company known for agility and personal attention to its products and stakeholders. Our dedication to improving patients’ lives can be seen both in the products that we market and the therapies that are currently under development. Each day, we work diligently to bring new therapies and new indications to patients across multiple therapeutic areas. In addition to our dedication to serving patients, we embrace a culture that values honesty, creativity, and action, integrity in relationships, a passion for success, and good stewardship of Company resources. We offer our employees exciting challenges, unique opportunities, and a fast-paced environment that emphasizes innovation and achievement. Our headquarters are in Louisville, Kentucky, but you can find our team and partners throughout the U.S. and across the globe. To learn more about our mission and values, and for all US WorldMeds information, visit our site: http://www.usworldmeds.com. You can also follow us on Twitter at @USWorldMeds.

Company Details

Employees
85
Founded
-
Address
4441 Springdale Road, Louisville,kentucky 40241,united States
Phone
5027147914
Email
me****@****eds.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Louisville, Kentucky
Looking for a particular Us Worldmeds employee's phone or email?

Us Worldmeds Questions

News

US WorldMeds acquires Adaptimmune cell-therapy for $55M - Lane Report

US WorldMeds acquires Adaptimmune cell-therapy for $55M Lane Report

US WorldMeds takes over quartet of Adaptimmune cell therapies in $55m deal - BioXconomy

US WorldMeds takes over quartet of Adaptimmune cell therapies in $55m deal BioXconomy

Curant Rare Announces Exclusive Pharmacy Partnership for IWILFIN™, the First and Only FDA-Approved Oral Maintenance Therapy Shown to Cut the Risk of High-Risk Neuroblastoma Relapse in Half - Business Wire

Curant Rare Announces Exclusive Pharmacy Partnership for IWILFIN™, the First and Only FDA-Approved Oral Maintenance Therapy Shown to Cut the Risk of High-Risk Neuroblastoma Relapse in Half Business Wire

Adaptimmune's Groundbreaking Cell Therapy Assets Acquired by US WorldMeds in $85M Strategic Deal - Stock Titan

Adaptimmune's Groundbreaking Cell Therapy Assets Acquired by US WorldMeds in $85M Strategic Deal Stock Titan

US WorldMeds Advances Partnership With FEMA And Healthcare Ready During Coronavirus Pandemic - PR Newswire

US WorldMeds Advances Partnership With FEMA And Healthcare Ready During Coronavirus Pandemic PR Newswire

US WorldMeds Launches ZIMHIDirect.com - GlobeNewswire

US WorldMeds Launches ZIMHIDirect.com GlobeNewswire

Epinephrine syringes recalled. Needle clogging can have ‘consequences including death’ - Miami Herald

Epinephrine syringes recalled. Needle clogging can have ‘consequences including death’ Miami Herald

US WorldMeds gets FDA approval for childhood cancer drug - The Business Journals

US WorldMeds gets FDA approval for childhood cancer drug The Business Journals

US WorldMeds' Iwilfin bags FDA nod as 1st oral maintenance treatment for high-risk neuroblastoma - Fierce Pharma

US WorldMeds' Iwilfin bags FDA nod as 1st oral maintenance treatment for high-risk neuroblastoma Fierce Pharma

Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand - PR Newswire

Norgine B.V. and US WorldMeds enter into exclusive licensing agreement to commercialise DFMO (eflornithine) in Europe, Commonwealth of Independent States, Australia and New Zealand PR Newswire

US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg Tablets - MultiVu

US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg Tablets MultiVu

First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms - Medical Professionals Reference

First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms Medical Professionals Reference

US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer - Business Wire

US WorldMeds Announces FDA Approval of IWILFIN™ (eflornithine) to Strengthen Fight Against Aggressive Childhood Cancer Business Wire

Supernus to Acquire CNS Portfolio from US WorldMeds - GlobeNewswire

Supernus to Acquire CNS Portfolio from US WorldMeds GlobeNewswire

US WorldMeds Reaches Agreement With Walgreens To Make Immediately Available LUCEMYRA® (lofexidine) In Pharmacies Across The Nation - PR Newswire

US WorldMeds Reaches Agreement With Walgreens To Make Immediately Available LUCEMYRA® (lofexidine) In Pharmacies Across The Nation PR Newswire

Louisville is headquarters haven - Lane Report

Louisville is headquarters haven Lane Report

High-Dose Naloxone Product Giving People Hope to Help Combat Growing Opioid Overdose Trend - Business Wire

High-Dose Naloxone Product Giving People Hope to Help Combat Growing Opioid Overdose Trend Business Wire

Fighting America's Opioid Crisis: Physicians And Consumers Believe Lack Of Education Around How To Discontinue Opioids Is A Huge Barrier - PR Newswire

Fighting America's Opioid Crisis: Physicians And Consumers Believe Lack Of Education Around How To Discontinue Opioids Is A Huge Barrier PR Newswire

FDA Approves US WorldMeds' LUCEMYRA™ (lofexidine) After Priority Review for the Management of Opioid Withdrawal Symptoms - PR Newswire

FDA Approves US WorldMeds' LUCEMYRA™ (lofexidine) After Priority Review for the Management of Opioid Withdrawal Symptoms PR Newswire

US WorldMeds gets a new home for the holidays - The Business Journals

US WorldMeds gets a new home for the holidays The Business Journals

Top Us Worldmeds Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant